Quote:

---

CytoDyn’s rising share price, Yorkville’s financial backing, and the upcoming approval of 500 million new shares signals growing support for the company’s plans—particularly its effort to validate earlier findings that Leronlimab can convert “cold” tumors to “hot,” potentially enabling synergy with multiple checkpoint inhibitors and attracting major pharmaceutical partners. This “Prime and Pair” mechanism could foster long-term collaboration with several big pharma companies, supported by ongoing FDA discussions that may lead to trial redesigns allowing earlier use of ICIs. A series of “breadcrumbs”—S3 filings, a wealthy benefactor, Yorkville’s investment, and strengthening stock action—are interpreted as signs that CytoDyn is moving toward stability, partnerships, and eventual validation of Leronlimab’s intended role.

---